Leading pharmaceutical company Ranbaxy Laboratories Ltd on Wednesday, said its wholly owned subsidiary Ranbaxy Malaysia Sdn Bhd (RMSB) has launched the first generics version of Atorvastatin, used for lowering cholesterol, under the brand name 'Storvas' in Malaysia.
The product 'Storvas' would be made available through all major general practitioners, pharmacies and hospitals in Malaysia and would be sold in dosage forms of 10 mg, 20 mg and 40 mg, Ranbaxy informed the Bombay Stock Exchange.
"Ranbaxy is proud to be the first company to launch the generic alternatives of Atorvastatin and Oseltamivir in Malaysia. It is our constant endeavour to offer affordable and safe generics of high quality to the patients in Malaysia and provide support to the government's healthcare plan," RMSB Managing Director T Jeyabalan said.
The company has received approvals from the Drugs Control Authority of Malaysia to manufacture and market the products, which are being produced at its facility in Malaysia.
The major therapeutic focus areas of RMSB include cardiovasculars, antibiotics and gastrointestinals, some of which, have leadership positions in the hospitals, general practitioners and pharmacy segments.
Earlier in July, RMSB became the first company to receive approvals to market generic Oseltamavir and was awarded a contract for supply to the Malaysian government.
The product marketed under the brand name, Fluhalt, is an antiviral used for treatment of H5N1 virus and is available in dosage form of 75 mg capsules.
Earlier in July, RMSB became the first company to receive approvals to market generic Oseltamavir and was awarded a contract for supply to the Malaysian government.
The product marketed under the brand name, Fluhalt, is an antiviral used for treatment of H5N1 virus and is available in dosage form of 75 mg capsules.
Ranbaxy entered Malaysia in 1983, with the formation of a joint venture between RLL and Malaysian shareholders.